Omni Bio Pharm Inc (OMBP) 0.0247 $OMBP World Gouty

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Omni Bio Pharm Inc (OMBP) 0.0247 $OMBP

World Gouty Arthritis (Gout) Pipeline Review, H2 2015
M2 - Wed Jan 06, 8:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/2jx4t4/gouty_arthritis) has announced the addition of the "Gouty Arthritis (Gout) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Report Coverage - Gouty Arthritis (Gout) Overview - Therapeutics Development - Pipeline Products for Gouty Arthritis (Gout) - Overview - Pipeline Products for Gouty Arthritis (Gout) - Comparative Analysis - Gouty Arthritis (Gout) - Therapeutics under Development by Companies - Gouty Arthritis (Gout) - Therapeutics under Investigation by Universities/Institutes - Gouty Arthritis (Gout) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Unknown Stage Products - Gouty Arthritis (Gout) - Products under Development by Companies - Gouty Arthritis (Gout) - Products under Investigation by Universities/Institutes - Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development Companies Mentioned - AstraZeneca Plc - Celtaxsys, Inc. - CymaBay Therapeutics, Inc. - Delenex Therapeutics AG - Immune Response BioPharma, Inc. - IOmet Pharma - JW Pharmaceutical Corporation - LG Life Science LTD. - Monosol Rx, LLC - Nimbus Therapeutics, LLC - Omni Bio Pharmaceutical Inc. - Opsona Therapeutics Limited - PLx Pharma Inc. - Polaris Pharmaceuticals, Inc. - Selecta Biosciences, Inc. - Takeda Pharmaceutical Company Limited - Teijin Limited - TWi Pharmaceuticals, Inc. - Wellstat Therapeutics Corporation For more information visit http://www.researchandmarkets.com/research/2j..._arthritis
AZN: 33.83 (-0.02), CBAY: 2.34 (+0.03), PLXP: ()

Gouty Arthritis (Gout) Pipeline Review, H1 2015 - 20 Companies & 37 Drug Profiles
M2 - Thu Jul 09, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zcbqd/gouty_arthritis) has announced the addition of the "Gouty Arthritis (Gout) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Celtaxsys, Inc. - CymaBay Therapeutics, Inc. - Delenex Therapeutics AG - Immune Response BioPharma, Inc. - IOmet Pharma - JW Pharmaceutical Corporation - Kissei Pharmaceutical Co., Ltd. - LG Life Sciences, Ltd. - Nimbus Therapeutics, LLC - Nippon Chemiphar Co., Ltd. - Omni Bio Pharmaceutical Inc. - Opsona Therapeutics Ltd. - PLx Pharma Inc. - Polaris Pharmaceuticals, Inc. - Selecta Biosciences, Inc. - Takeda Pharmaceutical Company Limited - Teijin Pharma Limited - TWi Pharmaceuticals, Inc. - Wellstat Therapeutics Corporation For more information visit http://www.researchandmarkets.com/research/7z..._arthritis
AZN: 33.83 (-0.02), CBAY: 2.34 (+0.03)

Global Myocardial Infarction Pipeline Review 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6sc3q/myocardial) has announced the addition of the "Myocardial Infarction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Alligator Bioscience AB - AstraZeneca PLC - Athersys, Inc. - Bayer AG - CellProthera - Compugen Ltd. - CSL Limited - FibroGen, Inc. - Fina Biotech - Genextra S.p.a. - GlaxoSmithKline plc - GliaMed, Inc. - Hadasit Medical Research Services & Development Ltd - Lacer, S.A. - Lee's Pharmaceutical Holdings Limited - LegoChem Biosciences, Inc - LG Life Sciences, Ltd. - Ligand Pharmaceuticals, Inc. - Medestea Research & Production S.p.A. - Merck & Co., Inc. - Omni Bio Pharmaceutical Inc. - Pluristem Therapeutics Inc. - Polyphor Ltd. - Quantum Genomics SA - Recardio GmbH - Remedy Pharmaceuticals, Inc. - Targazyme, Inc. - Vicore Pharma AB - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/m6sc3q/myocardial
PSTI: 1.68 (+0.01), MRK: 63.58 (+0.03), AZN: 33.83 (-0.02), CGEN: 7.26 (+0.30), FGEN: 19.11 (+0.06), GSK: 44.41 (+0.29), ATHX: 1.98 (-0.03)

Global Graft Versus Host Disease (GVHD) Pipeline Report 2015 - Analysis of 43 Companies & 66 Drug Profiles
M2 - Mon Apr 27, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjmb6v/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbGenomics International, Inc. - Adienne Pharma & Biotech - Alder Biopharmaceuticals Inc. - Alexion Pharmaceuticals, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Bellicum Pharmaceuticals, Inc. - Biogen Idec Inc. - Dr. Falk Pharma GmbH - Enlivex Therapeutics Ltd - Escape Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Generon (Shanghai) Corporation Ltd. - Lycera Corp. - Mesoblast Limited - Millennium Pharmaceuticals, Inc. - MSM Protein Technologies, Inc. - Neopharm Ltd. - NeoStem, Inc. - Novartis AG - Omni Bio Pharmaceutical Inc. - Pharmacyclics, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - R-Tech Ueno, Ltd. - REGiMMUNE Corporation - Targazyme, Inc. - Therapix Biosciences Ltd - Tobira Therapeutics, Inc. - Xenikos B.V. For more information visit http://www.researchandmarkets.com/research/bj...ersus_host
BIIB: 318.17 (+1.36), PCYC: 261.25 (+1.70), PSTI: 1.68 (+0.01), NBS: 2.25 (-0.09), ALDR: 33.31 (unch), BLCM: 18.61 (-0.04), ALXN: 137.42 (+0.89), ATHX: 1.98 (-0.03), TBRA: 4.85 (-0.03), NVS: 81.36 (+0.04)

Omni Bio Announces Presentation of Phase 1/2 Clinical Data for AAT at American Heart Association Scientific Sessions
Marketwired - Wed Nov 19, 3:20PM CST
Omni Bio Pharmaceutical, Inc. (PINKSHEETS: OMBP) ("Omni Bio" , an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today the presentation of Phase 1/2 clinical data for plasma-derived alpha-1 antitrypsin ("p-AAT" , demonstrating its ability to inhibit the inflammatory response in patients with acute ST-elevation myocardial infarction ("STEMI" , the most severe type of heart attack. The data were presented yesterday in a poster at the American Heart Association Scientific Sessions 2014, in Chicago. Importantly, these latest clinical findings further highlight the potential value of Omni Bio's first-in-class recombinant AAT candidate, AAT-Fc.

Omni Bio Successfully Completes Cell Line Optimization for Novel Recombinant Biologic
Marketwired - Wed Nov 19, 3:18PM CST
Omni Bio Pharmaceutical, Inc. (OTCBB: OMBP) ("Omni Bio" , an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today its manufacturing partners, Patheon and Sigma-Aldrich Fine Chemicals (SAFC), have successfully identified several high-expression cell lines able to produce Omni Bio's novel recombinant alpha-1 antitrypsin molecule (AAT-Fc) in large enough quantities to be considered commercially viable. This is a highly significant de-risking milestone that enables Omni Bio to move toward IND-enabling toxicology studies with the first and only pharmaceutically feasible recombinant AAT candidate currently in development.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 37

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 64

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 106

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 63

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 85

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 23

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 160

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 49

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 348

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading

Top 5 Most Recently Viewed Articles

Flow Beverage Welcomes José Bautista as Advisor and Announces Fundraising Progress

Updated Category News Views 336

Flow Beverage Corp. Welcomes José Bautista as Strategic Advisor Flow Beverage Corp. (TSX:FLOW; OTCQX:FLWBF) has recently made a significant move by bringing on board José Bautista as a Strategic Advisor. This addition is seen as a promising enhancement to the company's team, aligning with its dedication to excellence and innovation in the beverage sector. Background of...

Continue Reading
Milan Laser Hair Removal Marks a Significant 400 Clinic Milestone

Updated Category News Views 207

Milan Laser Hair Removal Reaches 400 Clinics Nationwide The leading provider in laser hair removal achieves a remarkable milestone with nationwide expansion efforts. Milan Laser Hair Removal, the hallmark of laser hair removal in the nation, proudly celebrates the grand opening of its 400th clinic, symbolizing a major advancement in its rapid expansion across the country....

Continue Reading
Global Vertical Roller Mill Market Expands to USD 1.04 Billion

Updated Category News Views 215

Understanding the Global Vertical Roller Mill Market The Vertical Roller Mill (VRM) market is anticipated to experience significant growth in the coming years. Currently valued at approximately USD 608.5 million in 2024, projections indicate that it will reach USD 1,041.2 million by 2033, achieving a compound annual growth rate (CAGR) of 6.1%. This increase is largely due...

Continue Reading
Pulsar Helium Provides Insights on Progress at Topaz Project

Updated Category News Views 313

Pulsar Helium Develops Well-Testing Strategy at Topaz Project Pulsar Helium Inc. (AIM: PLSR, TSXV: PLSR, OTCQB: PSRHF), a leading helium development company, has recently provided valuable updates regarding its well-testing activities at the Topaz project, located in Minnesota. This momentous phase in the project holistically aims to assess helium extraction capabilities...

Continue Reading
Trade Disclosures: Treatt plc's Key Operations Analyzed

Updated Category News Views 178

Understanding Recent Trade Disclosures by Treatt plc Treatt plc, a company known for its expertise in manufacturing and distributing essential oils and flavouring agents, operates in a competitive sector where trade disclosures play a crucial role in maintaining transparency and building investor trust. As we delve into the recent disclosures made by Treatt plc, we'll...

Continue Reading